Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome (Annals of Clinical Microbiology and Antimicrobials)

Background: Rifaximin is a minimally absorbed antibiotic with high luminal activity, used to treat various gastrointestinal diseases. Although rifaximin has been proposed as first line treatment for small intestinal bacterial overgrowth (SIBO), few data are available regarding its efficacy in non-IBS subjects. We aimed to assess the ability of rifaximin to normalize lactulose-H2 breath tests in non-IBS subjects with symptoms suggestive of SIBOMaterials and methodsConsecutive non-IBS patients presenting with bloating and flatulence were prospectively recruited and submitted to lactulose-H2 breath testing (LBT). Patients who had a positive result were offered rifaximin 1200?mg daily for 10?days. Breath testing was repeated two weeks after treatment completion in all patients in order to assess for response. Results: A total of 19 patients with a positive result received rifaximin and repeated the breath test (7 (36.8%) males, age 56.5???17.6?years). The mean peak hydrogen excretion was 13.7???2.8 and 10.3???7.3?ppm at baseline and following rifaximin treatment, respectively (t?=?1.98, p?=?0.06). LBT normalized in 8/19 (42.1%) subjects. No patients reported symptom resolution. No adverse events were reported.DiscussionStrengths include the study`s prospective design. Limitations include the small sample size and open label design. Conclusion: Rifaximin was not effective in normalizing LBT in our cohort of non-IBS subjects with symptoms suggestive of SIBO.